Fletikumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Target | IL20 |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 1357158-22-5 |
| ChemSpider | none |
| ChEMBL | CHEMBL3301580 |
| Chemical and physical data | |
| Formula | C6494H10000N1728O2050S44 |
| Molar mass | 146.5 kg/mol |
Fletikumab[1] is a monoclonal antibody designed for the treatment of rheumatoid arthritis.[2]
This drug was being developed by Novo Nordisk A/S until Novo ceased work in inflammation.
References
- ↑ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 110" (PDF). WHO Drug Information. 27 (4).
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Fletikumab, American Medical Association.
This article is issued from Wikipedia - version of the 6/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.